RIO DE JANEIRO, BRAZIL - The Immunobiological Technology Institute of the Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz) has restarted, on May 25, production of the Oxford/AstraZeneca Covid-19 vaccine, which had been suspended since last Thursday, May 20.
Production was resumed after the arrival of a new shipment of the active pharmaceutical ingredient (API) from China on Saturday, May 22.
Last weekend, Fiocruz received enough raw material to produce 12 million doses, which ensures the production of vaccines until the third week of June and uninterrupted deliveries to the National Immunization Program (PNI) until July 3.
The API is considered . . .